Dupixent® Lawsuits Explained: CTCL & Skin Cancer Claims | Know Your Legal Options

Dupixent® (dupilumab) is a widely prescribed injectable medication used to treat eczema, asthma, and other inflammatory conditions. However, emerging reports and lawsuits allege a possible link between Dupixent use and the development or worsening of Cutaneous T-Cell Lymphoma (CTCL)—a rare form of skin cancer. In this video, SSKB Managing partner Jeff Kimmel explain: What CTCL is and how it may be connected to Dupixent Which patients may qualify for a Dupixent lawsuit The types of injuries and diagnoses involved What legal options may be available to affected patients and families If you or a loved one were diagnosed with CTCL or experienced worsening lymphoma symptoms after using Dupixent®, you may be entitled to financial compensation. 📞 Free & confidential case review available Visit sskblaw.com or contact our firm to learn more about your legal rights at 800-675-8556. This video is for informational purposes only and does not constitute legal or medical advice.